Journal article
Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
BMC cancer, Vol.11(1), pp.354-354
08/16/2011
DOI: 10.1186/1471-2407-11-354
PMCID: PMC3174931
PMID: 21846341
Abstract
Background: We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment.
Methods: We analyzed patient surveys and medical records for a population-based cohort with metastatic colorectal cancer treated in multiple regions and health systems in the United States (US). Eligible patients were diagnosed with metastatic colorectal cancer and initiated first-line chemotherapy after US Food & Drug Administration (FDA) bevacizumab approval in February 2004. First-line bevacizumab therapy was defined as receiving bevacizumab within 8 weeks of starting chemotherapy for metastatic colorectal cancer. We evaluated factors associated with first-line bevacizumab treatment using logistic regression.
Results: Among 355 patients, 31% received first-line bevacizumab in the two years after FDA approval, including 26% of men, 41% of women, and 16% of those >= 75 years. Use rose sharply within 6 months after FDA approval, then plateaued. 20% of patients received bevacizumab in combination with irinotecan; 53% received it with oxaliplatin. Men were less likely than women to receive bevacizumab (adjusted OR 0.55; 95% CI 0.32-0.93; p = 0.026). Patients >= 75 years were less likely to receive bevacizumab than patients < 55 years (adjusted OR 0.13; 95% CI 0.04-0.46; p = 0.001).
Conclusions: One-third of eligible metastatic colorectal cancer patients received first-line bevacizumab shortly after FDA approval. Most patients did not receive bevacizumab as part of the regimen used in the pivotal study leading to FDA approval.
Details
- Title: Subtitle
- Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
- Creators
- S. Yousuf Zafar - Durham VA Medical CenterJennifer L. Malin - University of California, Los AngelesSteven C. Grambow - Durham VA Medical CenterDavid H. Abbott - Durham VA Medical CenterDeborah Schrag - Dana-Farber Cancer InstituteJane T. Kolimaga - Durham VA Medical CenterLeah L. Zullig - Durham VA Medical CenterJane C. Weeks - Dana-Farber Cancer InstituteMona N. Fouad - University of Alabama at BirminghamJohn Z. Ayanian - Brigham and Women's HospitalRobert Wallace - University of IowaKatherine L. Kahn - RAND CorporationPatricia A. Ganz - University of California, Los AngelesPaul Catalano - Dana-Farber Cancer InstituteDee W. West - Stanford MedicineDawn Provenzale - Duke UniversityCancer Care and Outcomes Research and Surveillance (CanCORS) Consortium
- Resource Type
- Journal article
- Publication Details
- BMC cancer, Vol.11(1), pp.354-354
- DOI
- 10.1186/1471-2407-11-354
- PMID
- 21846341
- PMCID
- PMC3174931
- NLM abbreviation
- BMC Cancer
- ISSN
- 1471-2407
- eISSN
- 1471-2407
- Publisher
- Springer Nature
- Number of pages
- 12
- Grant note
- 03-438MO-03 / Agency for Healthcare Research Quality; United States Department of Health & Human Services; Agency for Healthcare Research & Quality HSRD CRS 02-164 / Department of Veterans Affairs; US Department of Veterans Affairs U01CA093344; U01CA093329; R25CA116339; U01CA093332; U01CA093324; U01CA093339; U01CA093326; U01CA093348 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) U01 CA093344; U01 CA093332; U01 CA093324; U01 CA093348; U01 CA093329; U01 CA093339; U01 CA 093326 / National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Genentech; Roche Holding KL2RR024127 / NATIONAL CENTER FOR RESEARCH RESOURCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR)
- Language
- English
- Date published
- 08/16/2011
- Academic Unit
- Epidemiology; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984363591202771
Metrics
6 Record Views